Megalotect

Human Cytomegalovirus Immunoglobulin, the active ingredient in Megalotect, is an immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity to prevent cytomegalovirus infection in transplant recipients and to treat CMV disease in immunocompromised patients.

GNH USA supplies Megalotect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The product complies with European Union regulatory standards and is distributed under strict quality‑assured conditions. It is available for global procurement to support specialized care teams.

Megalotect is an immunoglobulin used in the management of cytomegalovirus‑related conditions. - Solid organ transplant recipients: reduces the risk of primary CMV infection after transplantation. - Hematopoietic stem cell transplant recipients: helps prevent CMV reactivation during the post‑transplant period. - Immunocompromised patients with active CMV disease: aids viral clearance and clinical improvement.

Adverse reactions may occur with any intravenous immunoglobulin preparation.

Common Side Effects: - Fever or chills during or shortly after infusion. - Headache or mild dizziness. - Nausea or mild gastrointestinal discomfort. - Transient rash or urticaria at the infusion site.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Thromboembolic events such as deep‑vein thrombosis. - Acute renal dysfunction or hemolysis. - Aseptic meningitis or severe neurologic symptoms.

Megalotect should be used with careful clinical monitoring. - Assess CMV serostatus: verify patient’s CMV immunity before administration. - Monitor infusion reactions: observe for fever, rash, or respiratory symptoms during infusion. - Evaluate renal function: adjust or discontinue if renal impairment develops. - Contraindicated in patients with known IgA deficiency and anti‑IgA antibodies. - Use with caution in pregnancy or breastfeeding: safety not established. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid): - Concurrent use of other CMV hyperimmune globulins: may lead to excessive antibody load. - Administration with live vaccines: can interfere with vaccine efficacy and safety.

Moderate Interactions (Monitor Closely): - Corticosteroids: may diminish the therapeutic effect of the immunoglobulin. - Antiviral agents (e.g., ganciclovir): additive antiviral activity may require monitoring. - Chemotherapy agents: increased risk of infusion‑related reactions. - Nephrotoxic drugs: monitor renal function closely during combined use.